Litigation Details for Sucampo AG v. Anchen Pharmaceuticals Inc. (D. Del. 2013)

« Back to Dashboard

Sucampo AG v. Anchen Pharmaceuticals Inc. (D. Del. 2013)

Docket		Date Filed	2013-02-07
Court	District Court, D. Delaware	Date Terminated	2014-12-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	TAKEDA PHARMACEUTICALS AMERICA INC.
Patents	6,414,016; 7,795,312; 8,026,393; 8,071,613; 8,097,653; 8,338,639; 8,389,542
Attorneys	Joseph M. O'Malley
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Sucampo AG v. Anchen Pharmaceuticals Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-02-07				External link to document

Sucampo AG v. Anchen Pharmaceuticals, Inc. Litigation Summary, Case No. 1:13-cv-00202

Last updated: August 8, 2026

Sucampo AG v. Anchen Pharmaceuticals, Inc., No. 1:13-cv-00202, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware concerning Anchen's proposed generic version of Amitiza, Sucampo's lubiprostone product. Sucampo asserted patents covering lubiprostone and its use in treating gastrointestinal disorders after Anchen filed an abbreviated new drug application containing a Paragraph IV certification.

The case was resolved without a reported merits decision establishing infringement or invalidity. Its commercial significance arose from the timing of generic Amitiza entry, the scope of Sucampo's Orange Book-listed patent estate, and the distinction between this action and related lubiprostone litigation involving other generic manufacturers.

What was Sucampo AG v. Anchen Pharmaceuticals about?

The case was a Hatch-Waxman action triggered by Anchen's ANDA for generic lubiprostone capsules. Sucampo and its commercial partner, Takeda Pharmaceuticals, marketed lubiprostone as Amitiza for chronic idiopathic constipation and other approved gastrointestinal indications.

Item	Case information
Case	Sucampo AG v. Anchen Pharmaceuticals, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:13-cv-00202
Filing year	2013
Plaintiff	Sucampo AG
Defendant	Anchen Pharmaceuticals, Inc.
Product	Generic lubiprostone capsules
Reference product	Amitiza
Regulatory pathway	ANDA under the Hatch-Waxman Act
Certification	Paragraph IV
Principal patents at issue	U.S. Patent Nos. 6,583,174 and 7,795,312
Outcome	Terminated without a reported final merits judgment

The complaint alleged that Anchen's ANDA filing constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). The filing permitted Sucampo to sue before commercial launch and triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).

Which patents did Sucampo assert against Anchen?

The case concerned at least U.S. Patent Nos. 6,583,174 and 7,795,312, patents associated with lubiprostone and its therapeutic use. Patent ownership and enforcement rights for Amitiza-related patents involved Sucampo and related commercial entities, while Takeda held the U.S. marketing relationship for Amitiza during the relevant period.

U.S. Patent No. 6,583,174

The '174 patent covered prostaglandin derivatives, including lubiprostone, and therapeutic uses involving gastrointestinal disorders. The patent was central to early Amitiza litigation and was also litigated in Sucampo's case against Dr. Reddy's Laboratories.

The '174 patent had an original 20-year patent term tied to its earliest effective nonprovisional filing date. Its ordinary term was substantially shorter than later continuation patents in the Amitiza estate. The patent's expiration limited its ability to block generic entry after the statutory term ended.

U.S. Patent No. 7,795,312

The '312 patent was a later patent in the lubiprostone estate and addressed therapeutic use of lubiprostone. It provided Sucampo with a later-dated patent position than the '174 patent and was relevant to the timing of generic entry.

The patent's enforceability and expiration date had to be analyzed separately from the '174 patent. A Paragraph IV challenge to one patent did not eliminate the legal effect of other valid, unexpired Orange Book-listed patents covering the same product or approved use.

Patent scope and claim risk

The asserted patents did not operate as a single undifferentiated block. Anchen's exposure depended on:

1. The exact ANDA formulation and dosage strengths.
2. The proposed labeling.
3. Whether the ANDA instructions induced use covered by the asserted method claims.
4. Whether the asserted claims survived validity challenges.
5. The expiration and Orange Book status of each patent.

This distinction was important because a generic applicant could avoid liability on a method-of-use patent through a section viii statement or a label carve-out, but only if the proposed labeling omitted the patented indication and did not encourage the patented use.

How did the Paragraph IV challenge affect the case?

Anchen's Paragraph IV certification represented its position that the relevant Sucampo patents were invalid, unenforceable, or would not be infringed by the proposed generic product. The certification created the statutory basis for Sucampo's infringement action.

The filing had three principal consequences:

• It gave Sucampo an immediate cause of action under 35 U.S.C. § 271(e)(2).
• It generally imposed a 30-month stay on FDA approval, subject to statutory exceptions.
• It created a potential first-filer or early-entry issue if Anchen was among the first applicants to submit a qualifying Paragraph IV certification.

A Paragraph IV certification is not an adjudication of patent invalidity. It is the ANDA applicant's legal position. The patent holder still must prove infringement, while the ANDA applicant may challenge validity, enforceability, or claim construction.

What was the litigation outcome?

The case did not produce a reported trial judgment or Federal Circuit merits opinion. The docket reflects termination of the action without a public merits ruling determining that Anchen infringed the asserted claims or that the patents were invalid.

The absence of a merits decision is commercially significant. It means the case did not create binding claim-construction or validity precedent against either party. It also prevents the case from being treated as a definitive holding on the enforceability of the Amitiza patent estate.

A negotiated resolution appears to have ended the dispute. Public docket materials do not establish a complete set of settlement terms, including any precise authorized-entry date, supply arrangement, royalty structure, or restrictions on Anchen's launch. Those terms should not be inferred from the dismissal alone.

Was there a settlement agreement in Sucampo v. Anchen?

The action ended without a publicly reported merits judgment, consistent with resolution by settlement or another negotiated termination. A dismissal does not, by itself, disclose:

• Whether Anchen received a license.
• Whether Anchen obtained an agreed launch date.
• Whether the parties entered into a co-promotion or supply arrangement.
• Whether Sucampo received a royalty.
• Whether the agreement contained acceleration, forfeiture, or no-challenge provisions.

Hatch-Waxman settlements may be subject to federal filing and antitrust review requirements under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The public case docket and FDA materials should be read separately from any confidential agreement.

What was the Orange Book status of Amitiza?

Amitiza was approved under NDA 021908 for lubiprostone capsules. The product was associated with Sucampo and Takeda, with later ownership and commercialization arrangements changing over time.

The relevant Orange Book analysis required review of:

• Listed drug substance patents.
• Listed drug product or formulation patents.
• Method-of-use patents.
• Patent delisting or expiration events.
• The ANDA applicant's certification for each listed patent.

The '174 and '312 patents were among the principal patents litigated in the early generic Amitiza cases. Later patents and regulatory listings could affect generic entry even after an earlier patent expired. Patent term, pediatric exclusivity, regulatory exclusivity, and the availability of a label carve-out were separate issues.

FDA approval of an ANDA also required resolution of each applicable listed patent or the expiration of the relevant statutory stay. The end of one patent did not automatically authorize launch if another valid, unexpired patent remained enforceable.

How did this case compare with related Amitiza litigation?

Sucampo's litigation against Anchen formed part of a broader generic challenge to Amitiza. Related cases included litigation against Dr. Reddy's Laboratories and other ANDA applicants.

Issue	Sucampo v. Anchen	Related Amitiza litigation
Product	Generic lubiprostone	Generic lubiprostone
Legal basis	Hatch-Waxman infringement	Hatch-Waxman infringement
Key patents	'174 and '312	Included '174, '312, and later patents
Merits ruling	No reported final merits ruling	Some related cases produced substantive decisions
Commercial effect	Restricted Anchen pending resolution	Helped define broader generic-entry risk
Precedential value	Limited	Depended on the specific decision and claims

Sucampo AG v. Dr. Reddy's Laboratories, Inc. generated reported Federal Circuit litigation involving the '174 and '312 patents. That litigation is analytically relevant but should not be conflated with the Anchen docket. A decision in one defendant's case did not automatically resolve every other ANDA applicant's infringement or validity defenses.

What generic-entry risks did Anchen face?

Anchen's principal risks were regulatory delay, patent-infringement liability, and the economic cost of entering a market with an established branded product.

Regulatory risk

The Paragraph IV certification exposed Anchen to a 30-month approval stay unless the stay was shortened, terminated, or otherwise rendered inapplicable. FDA approval timing depended on the litigation status of each asserted patent and the terms of any resolution.

Patent risk

The asserted patents created risk if Anchen's ANDA product or label fell within the claims. Method-of-use claims presented a specific risk because a generic label could still support induced infringement if the label encouraged the patented indication.

Commercial risk

A generic launch could face:

• Reduced reimbursement access.
• Rapid price erosion.
• Brand-side contracting responses.
• Limited market share if multiple generic applicants launched together.
• Royalty obligations under a settlement license.

An authorized or licensed launch could materially reduce litigation risk but would still affect Sucampo and Takeda's net sales, pricing, and market share.

Did the case establish that the Amitiza patents were valid?

No. The Anchen action did not result in a reported decision confirming validity or infringement. Any conclusion that Sucampo prevailed on the merits would overstate the docket record.

The broader Amitiza patent estate also had mixed litigation exposure. Validity depended on the specific asserted claims, prior art, written description, enablement, obviousness, indefiniteness, and prosecution history. Claim-by-claim analysis was required.

The absence of a merits judgment left the parties without a case-specific judicial ruling on:

• Claim construction.
• Obviousness.
• Written description.
• Enablement.
• Indefiniteness.
• Inequitable conduct.
• Induced infringement.
• The effect of a proposed label carve-out.

What manufacturing and formulation IP barriers applied?

Lubiprostone is a small-molecule active pharmaceutical ingredient, so the case did not present biosimilar-style biologic manufacturing barriers. The relevant barriers were conventional small-molecule patent and regulatory barriers.

Potential technical barriers included:

• API purity and impurity control.
• Capsule formulation reproducibility.
• Low-dose content uniformity.
• Stability and dissolution performance.
• Manufacturing process validation.
• Bioequivalence requirements.
• Labeling restrictions for patented indications.

These issues could affect ANDA approval and launch economics even where the principal composition-of-matter patent had expired. Formulation and method-of-use patents could extend practical protection beyond the earliest patent in the estate.

What is the current litigation significance of the case?

The case has limited precedential value because it ended without a reported final merits decision. Its primary value is historical and commercial:

1. It confirms that Anchen challenged Amitiza patent protection through the ANDA Paragraph IV process.
2. It identifies the '174 and '312 patents as part of the asserted estate.
3. It shows that Sucampo pursued multiple generic applicants rather than relying on a single enforcement action.
4. It demonstrates that early Amitiza entry analysis required review of the full Orange Book listing, not only the earliest patent.
5. It does not establish a binding ruling on the validity, enforceability, or infringement of the asserted patents.

Key Takeaways

• Sucampo AG v. Anchen Pharmaceuticals, No. 1:13-cv-00202, was a Delaware Hatch-Waxman case involving generic lubiprostone and Amitiza.
• Sucampo asserted U.S. Patent Nos. 6,583,174 and 7,795,312.
• Anchen's Paragraph IV certification created the statutory infringement action and potential 30-month FDA approval stay.
• The case ended without a reported trial judgment or appellate merits decision.
• Publicly available records do not establish the complete terms of the parties' resolution.
• The case has limited precedential value but remains relevant to the chronology of Amitiza generic-entry disputes.
• Related litigation, Orange Book listings, patent expirations, and any settlement-specific launch license must be analyzed separately.

FAQs About Sucampo AG v. Anchen Pharmaceuticals

What drug was at issue in Sucampo v. Anchen?

The case concerned lubiprostone, the active ingredient in Amitiza, a prescription treatment for specified gastrointestinal disorders.

Was Anchen allowed to launch generic Amitiza immediately after the case ended?

The docket termination alone does not establish the launch date or the precise commercial rights granted to Anchen. Those issues depended on the parties' resolution and FDA approval status.

Did Sucampo win a patent trial against Anchen?

No reported final merits judgment establishes that Sucampo won a patent trial against Anchen.

Were the Amitiza patents composition patents or method-of-use patents?

The Amitiza estate included patents directed to lubiprostone and patents directed to therapeutic uses. The infringement analysis depended on the particular claims asserted against the ANDA.

Does the Anchen case control other generic Amitiza lawsuits?

No. The case was not a binding merits decision controlling unrelated defendants. Other Amitiza cases required separate analysis of the ANDA, asserted claims, defenses, and procedural history.

References

1. U.S. District Court for the District of Delaware. (2013). Sucampo AG v. Anchen Pharmaceuticals, Inc., No. 1:13-cv-00202, docket materials.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations (Orange Book), NDA 021908, Amitiza.

3. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,583,174: Prostaglandin derivatives for the treatment of gastrointestinal disorders.

4. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,795,312.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications, 21 C.F.R. § 314.107.

6. U.S. Code. (2024). Patent infringement under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).

7. U.S. Code. (2024). Abbreviated new drug applications and patent-related approval stays, 21 U.S.C. § 355(j).